pembrolizumab: Clinical Trials

2,589 trials of pembrolizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

772 completed, 575 recruiting, 457 active not recruiting, 374 terminated. 1616 Phase 2, 957 Phase 1, 348 Phase 3, 39 Early Phase 1, 25 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 21616Completed 443, Recruiting 352, Active not recruiting 289, Terminated 244, Unknown 114, Withdrawn 92, Not yet recruiting 74, Suspended 8
Phase 1957Completed 320, Recruiting 205, Terminated 175, Active not recruiting 147, Withdrawn 41, Unknown 39, Not yet recruiting 22, Suspended 7, Enrolling by invitation 1
Phase 3348Recruiting 116, Completed 88, Active not recruiting 80, Terminated 30, Not yet recruiting 17, Unknown 11, Withdrawn 6
Early Phase 139Completed 14, Active not recruiting 8, Terminated 5, Recruiting 4, Withdrawn 4, Unknown 2, Enrolling by invitation 1, Not yet recruiting 1
Not applicable25Unknown 7, Recruiting 6, Completed 5, Active not recruiting 2, Not yet recruiting 2, Terminated 2, Enrolling by invitation 1
Phase 413Recruiting 5, Completed 3, Not yet recruiting 2, Active not recruiting 1, Unknown 1, Withdrawn 1

Follow pembrolizumab: new trials by email Literature Review of pembrolizumab trials Research Report on pembrolizumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 3Not yet recruitingTranscenta Therapeutics (Hangzhou) Co., Ltd.8202027-06-302026-09-29
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer
Phase 1SuspendedUNC Lineberger Comprehensive Cancer Center62027-05-202026-04-23
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Larotrectinib, Pembrolizumab - Solid Tumor
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center222027-03-012026-09-28
Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma
Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 3Not yet recruitingNational Cancer Institute (NCI)4002027-02-102026-07-08
A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.
INCA33890, Pembrolizumab - Head and Neck Cancer Squamous Cell Carcinoma
Phase 2Not yet recruitingGroupe Oncologie Radiotherapie Tete et Cou782027-02-012026-10-22
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
Phase 2RecruitingMedical University of South Carolina552027-01-012026-10-15
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 2Not yet recruitingEmory University322027-01-012026-11-04
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma
Phase 2RecruitingCity of Hope Medical Center232027-01-012026-11-12
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer
Phase 2Not yet recruitingWashington University School of Medicine122026-12-312026-10-21
Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer
LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer
Phase 2Not yet recruitingCanadian Cancer Trials Group1602026-12-312026-10-27
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
RO7836748, Pembrolizumab, mFOLFIRINOX - Solid Tumors
Phase 1Not yet recruitingHoffmann-La Roche5402026-12-312026-10-30
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
ISM5939, Cisplatin, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1Not yet recruitingInSilico Medicine Hong Kong Limited1592026-12-302026-07-23
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer
Phase 3RecruitingExelixis6002026-12-182026-11-12
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 2RecruitingExelixis602026-12-152026-11-12
Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer
Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss
Phase 1 / Phase 2Not yet recruitingVA Office of Research and Development432026-12-072026-11-12
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Phase 2 / Phase 3Not yet recruitingNational Cancer Institute (NCI)3742026-12-042026-11-18
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma
Phase 2Not yet recruitingPeter MacCallum Cancer Centre, Australia302026-12-012026-10-26
Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma
LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab - Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm
Phase 2Not yet recruitingVA Office of Research and Development302026-12-012026-10-06
Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma
enfortumab vedotin and pembrolizumab (EV/P) - Urothelial Carcinoma (UC)
Phase 2Not yet recruitingUniversity of Florida392026-12-012026-09-14

Showing 20 of 2589. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (488)  ·  Melanoma (305)  ·  Squamous Cell Carcinoma of Head and Neck (249)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (196)  ·  Neoplasms (191)  ·  Triple Negative Breast Neoplasms (173)  ·  Neoplasm Metastasis (168)  ·  Breast Neoplasms (166)  ·  Lung Neoplasms (154)  ·  Colorectal Neoplasms (153)  ·  Carcinoma, Renal Cell (139)  ·  Head and Neck Neoplasms (129)  ·  Stomach Neoplasms (113)  ·  Ovarian Neoplasms (106)  ·  Carcinoma, Transitional Cell (99)

Sponsors

Merck Sharp & Dohme LLC (266)  ·  M.D. Anderson Cancer Center (75)  ·  National Cancer Institute (NCI) (73)  ·  Memorial Sloan Kettering Cancer Center (37)  ·  Dana-Farber Cancer Institute (31)  ·  Mayo Clinic (30)  ·  Eli Lilly and Company (21)  ·  Emory University (20)  ·  University of Chicago (20)  ·  Washington University School of Medicine (20)  ·  Astellas Pharma Global Development, Inc. (19)  ·  City of Hope Medical Center (19)  ·  GlaxoSmithKline (19)  ·  H. Lee Moffitt Cancer Center and Research Institute (18)  ·  Roswell Park Cancer Institute (18)

Countries

United States (1740)  ·  Spain (461)  ·  France (382)  ·  South Korea (376)  ·  Italy (351)  ·  United Kingdom (341)  ·  China (340)  ·  Australia (338)  ·  Canada (336)  ·  Germany (313)  ·  Japan (275)  ·  Poland (236)  ·  Taiwan (235)  ·  Belgium (202)  ·  Israel (180)

Top investigators

Mark Jones, MD (6)

Results publications

PMID 31395089, PMID 35101941, PMID 33300372, PMID 37699333, PMID 32305010, PMID 37465924, PMID 15800326, PMID 38642841, PMID 11698646, PMID 15771580, PMID 18565862, PMID 20516428, PMID 25891174, PMID 27718847, PMID 30202085, PMID 30736858, PMID 32450725, PMID 33360855, PMID 33416261, PMID 33792646, PMID 34754076, PMID 35421228, PMID 35623069, PMID 36648215, PMID 36923556, PMID 37037952, PMID 37598000, PMID 39230120, PMID 39462179, PMID 40117530, PMID 16227604, PMID 17360651, PMID 19188168, PMID 20636820, PMID 23724846, PMID 25891173, PMID 25977344, PMID 25979390, PMID 26028407, PMID 26712084, PMID 27093365, PMID 27138582, PMID 27247226, PMID 27646946, PMID 27745820, PMID 27863197, PMID 28212060, PMID 28271869, PMID 28291584, PMID 29395863

NIH funding

2023 (152), 2018 (63), 2019 (43), 2016 (42), 2017 (39), 2025 (34), 2015 (32), 2014 (20), P30CA138292 (19), U10CA180820 (14), P30CA060553 (13), U10CA180888 (12), P30CA015704 (11), U10CA180868 (10), P30CA033572 (9)